NetraMark Appoints Jan Sedway as Senior Vice President of Clinical Science to Accelerate Growth and Market Leadership
NetraMark Holdings (OTCQB: AINMF), an AI company specializing in clinical trial optimization, has appointed Dr. Jan Sedway as Senior Vice President of Clinical Science. Dr. Sedway brings over 20 years of leadership experience in clinical research and global operations, previously serving as Vice President of Clinical Development at Clario.
The appointment aligns with NetraMark's strategic expansion in the pharmaceutical industry, focusing on scaling its AI-powered solutions across psychiatry, oncology, and other therapeutic areas. Dr. Sedway's experience includes advancing digital biomarker solutions and driving operational excellence in global clinical trials, with previous leadership roles at Parexel and Syneos Health.
NetraMark Holdings (OTCQB: AINMF), società specializzata nell'uso dell'IA per ottimizzare gli studi clinici, ha nominato Dr. Jan Sedway Vicepresidente senior per la Scienza Clinica. Il dott. Sedway porta con sé oltre 20 anni di esperienza dirigenziale nella ricerca clinica e nelle operazioni globali, avendo ricoperto in precedenza il ruolo di Vice President of Clinical Development presso Clario.
La nomina è in linea con l'espansione strategica di NetraMark nel settore farmaceutico, mirata a scalare le sue soluzioni basate sull'IA in ambiti come psichiatria, oncologia e altre aree terapeutiche. L'esperienza del dott. Sedway include lo sviluppo di soluzioni basate su biomarcatori digitali e il miglioramento dell'eccellenza operativa negli studi clinici internazionali, con precedenti incarichi dirigenziali in Parexel e Syneos Health.
NetraMark Holdings (OTCQB: AINMF), una compañía de IA especializada en la optimización de ensayos clínicos, ha nombrado a Dr. Jan Sedway Vicepresidente Senior de Ciencia Clínica. El Dr. Sedway aporta más de 20 años de experiencia en liderazgo en investigación clínica y operaciones globales, habiendo sido previamente Vice President of Clinical Development en Clario.
El nombramiento se alinea con la expansión estratégica de NetraMark en la industria farmacéutica, con el objetivo de escalar sus soluciones impulsadas por IA en áreas como psiquiatría, oncología y otras áreas terapéuticas. La experiencia del Dr. Sedway incluye el avance de soluciones de biomarcadores digitales y la promoción de la excelencia operativa en ensayos clínicos globales, con roles previos en Parexel y Syneos Health.
NetraMark Holdings (OTCQB: AINMF)는 임상시험 최적화에 특화된 AI 기업으로, Dr. Jan Sedway를 임상과학 수석 부사장으로 임명했습니다. Sedway 박사는 임상 연구 및 글로벌 운영 분야에서 20년 이상의 리더십 경험을 보유하고 있으며, 이전에는 Clario에서 임상 개발 담당 부사장을 역임했습니다.
이번 임명은 정신과, 종양학 및 기타 치료 분야와 같은 영역에서 AI 기반 솔루션의 확장을 목표로 하는 NetraMark의 제약 산업 내 전략적 확장과 일치합니다. Sedway 박사의 경력에는 디지털 바이오마커 솔루션의 발전과 글로벌 임상시험에서의 운영 우수성 추진이 포함되며, 이전에는 Parexel 및 Syneos Health에서의 리더십 역할을 맡았습니다.
NetraMark Holdings (OTCQB: AINMF), une société d'IA spécialisée dans l'optimisation des essais cliniques, a nommé Dr. Jan Sedway Vice-président senior des sciences cliniques. Le Dr Sedway apporte plus de 20 ans d'expérience en direction de la recherche clinique et des opérations mondiales, et a précédemment occupé le poste de Vice President of Clinical Development chez Clario.
Cette nomination s'inscrit dans l'expansion stratégique de NetraMark dans l'industrie pharmaceutique, visant à déployer ses solutions alimentées par l'IA dans des domaines tels que la psychiatrie, l'oncologie et d'autres domaines thérapeutiques. L'expérience du Dr Sedway inclut le développement de solutions de biomarqueurs numériques et la promotion de l'excellence opérationnelle dans les essais cliniques mondiaux, avec des postes de direction antérieurs chez Parexel et Syneos Health.
NetraMark Holdings (OTCQB: AINMF), ein KI-Unternehmen, das sich auf die Optimierung klinischer Studien spezialisiert hat, hat Dr. Jan Sedway zum Senior Vice President für Klinische Wissenschaft ernannt. Dr. Sedway bringt mehr als 20 Jahre Führungserfahrung in der klinischen Forschung und globalen Betriebsführung mit und war zuvor Vice President of Clinical Development bei Clario.
Die Ernennung passt zur strategischen Expansion von NetraMark in der Pharmaindustrie, mit dem Fokus, KI-gestützte Lösungen in Bereichen wie Psychiatrie, Onkologie und weiteren Therapiegebieten zu skalieren. Dr. Sedways Erfahrung umfasst die Weiterentwicklung digitaler Biomarker-Lösungen und die Förderung operativer Exzellenz in globalen klinischen Studien; zuvor hatte er Führungspositionen bei Parexel und Syneos Health inne.
- None.
- None.
TORONTO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt:PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced the appointment of Jan Sedway, Ph.D., as Senior Vice President of Clinical Science.
As NetraMark strategically expands its footprint in the pharmaceutical industry, this appointment reinforces the Company’s commitment to scaling its offerings across psychiatry, oncology and other high-growth therapeutic areas. The global addressable market for AI-driven clinical trial optimization is projected to continue to expand rapidly, and NetraMark seeks to continue to capture market share with its proprietary technology and growing commercial pipeline.
Dr. Sedway brings over 20 years of leadership experience in clinical research and global operations. Most recently, she served as Vice President of Clinical Development at Clario, a global clinical trial endpoint technology leader, where she led scientific innovation efforts, developed capabilities across new therapeutic areas including dermatology and hematology, and provided scientific and clinical input into protocol design and implementation. Her work at Clario included advancing digital biomarker solutions and driving operational excellence in global clinical trials. Prior to her work at Clario, Dr. Sedway held leadership positions at Parexel and Syneos Health.
Dr. Sedway holds a Bachelor of Arts in Psychology from the University of Michigan at Ann Arbor. She received her Master of Arts in Psychology and Doctorate of Philosophy in Psychology from the University of North Carolina at Chapel Hill.
"We are thrilled to welcome Jan to the NetraMark leadership team," said Josh Spiegel, President of NetraMark. "Her depth of expertise in clinical innovation and operational execution directly aligns with our growth strategy as we continue to drive adoption of our AI-powered solutions. Jan’s leadership will help accelerate value delivery to our clients."
Dr. Sedway added, "NetraMark’s technology is reshaping the future of clinical trials by seeking to unlock critical insights from small, complex datasets and enabling precision trial design. I am excited to join this dynamic team and look forward to contributing to our clients’ success."
About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).
For more NetraMark information, see the company’s website and follow NetraMark on LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding how NetraMark may transform clinical trials, the Company’s strategic expansion and growth strategy, the potential of certain therapeutic areas, the global addressable market for AI driven clinical trial optimization, the potential for NetraMark to capture market share and the potential impact of Dr. Sedway on the Company’s value delivery to clients, which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.
When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Contact Information:
Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549
FAQ
Who is NetraMark's new Senior Vice President of Clinical Science?
What is Dr. Jan Sedway's background before joining NetraMark (AINMF)?
What therapeutic areas is NetraMark (AINMF) focusing on?
How does NetraMark's technology impact clinical trials?
